PharmaTelevision - ValiRx: Bioscience Innovation

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: ValiRx: Bioscience Innovation

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this interview, filmed during BioEurope 2008 in Madrid, Fintan Walton speaks with Satu Vainikka, CEO of ValiRx, an AIM listed biopharmaceutical company based in the UK. Focusing on epigenetics, ValiRx is developing novel technologies and products in oncology therapeutics and diagnostics. They act as a "mother" company to the two companies they have developed to concentrate on these separate goals: Cronos, focusing on cancer therapeutics; and ValiBIO, which focuses on cancer diagnostics. Within these companies, ValiRx has created unique partnerships with academia that allows them to utilise those distribution channels that have already been created and to provide the institution with revenue from future royalties. As subsequent complementary opportunities are identified by ValiRx, it is feasible that their portfolio of companies will continue to grow as they capitalise on their experience in transferring technologies and products into the commercial arena.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

ValiRx's role and key focus.

Fintan Walton:

Hello and welcome to PharmaVentures Business Review here live in Madrid. On this show I have Satu Vainikka, who is the CEO of ValiRx which is an AIM listed company based in the UK, welcome to the show.

Satu Vainikka:

Thank you.

Fintan Walton:

Satu, you were formerly the CEO of Cronos which was a company based in the UK still is.

Satu Vainikka:

Still is.

Fintan Walton:

And it's now part of the company called ValiRx and you are the CEO of that company it's an AIM listed company. What is the role of ValiRx? What are your what's your key focus as a biotechnology company?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Satu Vainikka

Chief Executive Officer

Satu Vainikka is a biotechnology entrepreneur with extensive experience in the biotechnology industry, technology commercialization, equity financing, and business management. Prior to her current role as a CEO of ValiRx, she was a founder, director and CEO of Cronos. Originally trained as a PhD molecular biologist/molecular geneticist, she adds the experience of eight years of research in molecular oncology and an MBA to her wealth of knowledge. Her previous roles include founder and executive director of biotech companies, and consultancy roles in healthcare technology commercialization, and entrepreneurship. In her past roles, Dr Vainikka has successfully developed business strategies, negotiated corporate and academic transactions, and raised funding for companies.

ValiRx

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncologytherapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases. ValiRx Plc listed on AIM in October 2006. ValiRx is creating a portfolio of innovative products through investment in specific development projects. ValiRx actively manages projects within this portfolio as a trading company and is not an investment vehicle. The diversity of projects that ValiRx is undertaking spreads the investment risk. Moreover, the business model minimizes the level of financial exposure associated with R&D since the bulk of the costs are borne by its academic partners in return for a royalty payment or, in the case of a commercial partner, an exclusive licensing agreement from which ValiRx derives revenue in the form of milestone and royalty payments. At this time, there are two portfolio companies, Cronos Therapeutics Ltd (www.cronostherapeutics.com) and ValiBIO SA (www.valibio.com).